Clinical Study on the Efficacy of Single-port Inflatable Mediastinoscopy Combined With Laparoscopic-assisted Small Incision Surgery and Thoracoscopy Combined With Laparoscopic Surgery for Radical Esophagectomy

Inclusion Criteria:

1. 18 years old ≤ age ≤ 75 years old, no gender limit;
2. Patients who are diagnosed as esophageal malignant tumor by cytology or histology, and agree to undergo surgical treatment;
3. The preoperative clinical tumor staging is T1-2N0-1M0 patients; or T3N1-2M0 patients undergo neoadjuvant treatment (neoadjuvant chemotherapy, neoadjuvant chemoradiation, neoadjuvant radiotherapy, neoadjuvant chemotherapy and immunotherapy, neoadjuvant radiotherapy and immunotherapy After treatment), assess the tumor to achieve partial response (PR) and surgical resection is feasible;
4. The tumor is located in the thoracic esophagus;
5. The tumor has not invaded the surrounding vital organs and has metastasized far away;
6. The function of major organs is basically normal: general anesthesia is acceptable for lung function; NYHA grade of heart function is 0\~1;
7. Voluntarily sign an informed consent form before the study. The patient and/or his legal representative have the ability to fully understand the content, process and possible adverse reactions of the experiment, and enable the patient to comply with the visits stipulated in the plan;

Exclusion Criteria:

1. People who suffer from other malignant tumors at the same time;
2. Patients with a history of esophagus or gastrectomy;
3. Patients with a history of mediastinal surgery or extensive abdominal cavity adhesion;
4. Patients with basic diseases such as cardiovascular and cerebrovascular diseases;
5. People suffering from mental, mental or neurological diseases;
6. Patients with cachexia and severe malnutrition who cannot tolerate surgery;
7. Recent recurrence of gastric ulcer, history of gastric bleeding and other serious underlying diseases;
8. Patients with surgical contraindications such as blood coagulation dysfunction, HIV antibody positive, and poorly controlled clinically severe infections;
9. Patients with other comorbid diseases (such as liver and kidney function abnormalities, etc.) or concomitant medications, which may have an impact on the results of this study based on the judgment of the investigator.
10. Patients who have participated in other clinical studies;
11. Others judged by the investigator to be unsuitable to participate in this clinical trial.